H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (NASDAQ:VIR) on Monday, setting a price target of $135, which is approximately 198.80% above the present share price of $45.18.
Trucchio expects Vir Biotechnology to post earnings per share (EPS) of -$0.83 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Vir Biotechnology, with an average price target of $75.2.
The analysts price targets range from a high of $135 to a low of $30.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.73 million and a net profit of -$108.4 million. The company's market cap is $5.78 billion.
According to TipRanks.com, H.C. Wainwright analyst Patrick Trucchio is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 5.5% and a 51.35% success rate.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.